SPECIAL REPORT: 2019 Biopharma Outlook – Facing an Uncertain Future

Xconomy

In this Xconomy Special Report, our veteran biotech journalists Alex Lash and Ben Fidler bring you deep insights, based on conversations with key industry leaders, on what 2019 and beyond hold for biopharmaceutical companies. After years of boom times, the U.S.

Entrepreneurshit. The Blog Post on What It’s Really Like.

Both Sides of the Table

The press who trusted me enough to report on our successes. Despite the fact that only the Lotto winners get reported. It’s 4.50am. Sunday morning. And I couldn’t sleep. I have much on my mind since I just returned from a week on the road. 5 days. 3 cities.

Report: Demand Media Targets Critical Blog

socalTECH

Santa Monica-based Demand Media , the online content publishing empire run by Richard Rosenblatt, is targeting a blog which has been posting internal documents and criticism of the company. According to a report from Forbes, the firm has sent a cease-and-desist letter to Demand Studio Sucks , alleging copyright infringement. demand media blog critical legal lawsuit

Should You Bother Targeting the Tech Blogs for Your PR Campaigns?

Both Sides of the Table

6 or 7 years ago when TechCrunch was at its peak market share (they are still strong but many more tech blogs have also popped up) there was a term for getting covered there called “the TechCrunch bounce.” that they probably read the main tech blogs.

BUZZMEDIA Buys Four Punk Rock Blogs

socalTECH

Los Angeles-based BUZZMEDIA , the growing online music publisher, reported this morning that it has acquired four punk rock sites, which it will use to create a new punk music group called AbsoluteVoices. Punknews.org was founded in 1998, providing online music news and a fan community; PropertyOfZack is a Tumblr blog focused on punk; Under The Gun Review focuses on entertainment, music, film, and comedy; and Alert The Press!

Mail.com Buys Entertainment Blog

socalTECH

Los Angeles-based Mail.com Media Corporation , which operates the email service Mail.com, said today that it has acquired an entertainment focused blog, DeadlineHollywoodDaily.com. DeadlineHollywoodDaily.com was founded by Nikki Finke, a former Newsweek, Los Angeles Times, and New York Magazine writer and reporter. Tags: mail.com mail media merger acquisition deadlinehollywooddaily blog content email

Report: Express Scripts Shuts Out Teva Migraine Drug, Prefers Rivals

Xconomy

The pharmacy benefits manager (PBM) is excluding a new drug from Teva Pharmaceutical from coverage while favoring two rival treatments instead, according to a report from Reuters. [ Updated 10/17/18, 2:52 p.m. See below.

Class 68

EY Report Suggests Improving Conditions for U.S. IPOs in 2018

Xconomy

Although there are still several days remaining in the first quarter of 2018, EY reports the number of first-quarter IPOs is 44 percent higher than the 25 offerings that occurred in the first quarter of 2017. IPO activity has been ticking up, with 36 IPOs raising more than $12.7

Gottlieb Reportedly On Tap to Lead FDA, and Biopharma Exhales

Xconomy

According to several news reports, the Trump administration will nominate Scott Gottlieb to be the new commissioner of the FDA, a selection that had the life sciences industry breathing a sigh of relief Friday afternoon.

News 84

Report: Biotech VCs Perpetuate Boardroom Gender Gap

Xconomy

If power in the business world is centered in the boardroom, women in biotech have a long way to go to get their fair share—and the venture community deserves much of the blame.

Study 80

The Rise of Robocalls and Cell Scams—and How to Stop Them

Xconomy

[ Updated 9:15 a.m., see below. ] Jen King was in a hurry to get out the door of her Bay Area home on a recent morning, and she missed a call to her cell phone because of it. The phone number that called her, she later discovered, was startling. “It It was my home phone calling me, which was not possible,” says King, who recently finished a doctorate in information science and now works at Stanford University.

The Painfully Poor Record of New Pain Drug Development: BIO Report

Xconomy

Some key points from the report: Pain drug developers have managed a meager 2 percent chance of gaining FDA approval for novel drugs, if they make. With the opioid epidemic showing little sign of letting up, new ways of treating chronic pain are desperately needed.

How the Rise of Beijing and Shanghai Tech May Impact Silicon Valley

Xconomy

But that is starting to change, as Asian cities—particularly in China—are snapping up more tech venture capital funding and exits, according to a new report from CB Insights. Silicon Valley tech startups pulled in the most funding of any metro region globally during the last six years at $140 billion, according to CB Insights’ Global Tech Hubs Report, which the New York-based research firm published Tuesday. When it comes to startup tech hubs, U.S.

San Diego Innovation Economy Extended Gains in 2015: Connect Report

Xconomy

That’s according to a report being released today by Connect, the local nonprofit group focused on technology and entrepreneurship. The Connect Innovation Report found that 405 software, technology, and life sciences startups were created last year in San Diego County.

Third-Quarter Report Shows Slowdown in VC Activity, & Top 10 Deals

Xconomy

Venture capital activity is gradually easing from last year’s peak, according to a new quarterly report put together by Seattle-based PitchBook and the National Venture Capital Association. deals (1,796 companies) during the third quarter that ended September 30, according to the inaugural “Venture Monitor” report released today. It was the fifth straight quarterly decline in the number of companies getting VC funding, according to the report.

Udacity Achieves 50,000 Nanodegree Grads Amid Company Reorganization

Xconomy

In a blogpost touting student successes, Udacity co-founder Sebastian Thrun (pictured above in 2014) said Nanodegree graduates are reporting average salary increases of 33 percent in the United States and Canada when they score new jobs after updating.

CrowdStrike Hauls In $200M, Reports Valuation Over $3 Billion

Xconomy

CrowdStrike , a Silicon Valley cybersecurity company that fends off hackers by patrolling the edge devices connected to a network, announced today it raised $200 million in a financing round that sets the company’s valuation at more than $3 billion.

VC Funding Surges in Fewer Deals in Third Quarter, and Top 10 Deals

Xconomy

“More dollars, fewer deals” has been a prevailing trend in venture funding over the past couple of years, and it was evident again in the three months that ended September 30, according to the latest Venture Monitor report.

Big Deals, Life Sciences Push U.S. VC in 2018 to Dot-Com Boom Levels

Xconomy

That’s according to PitchBook and the National Venture Capital Association’s Venture Monitor report, released this week, which tallied nearly 9,000 deals made last year, through which venture investors sunk $130.9

Amid Gender Gap Talk, Mentor Network Emerges For Women In Health, Bio

Xconomy

It’s been more than a year since an infamous party with hired models in cocktail dresses captured the biotech community’s attention at the 2016 J.P. Morgan conference. There has been plenty of talk since about closing biotech’s notable gender gap. At this year’s J.P

ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More

Xconomy

[ Note: Ben Fidler co-authored this report.] This weekend, San Diego will host the annual American Society of Hematology conference, the largest U.S.

Guide 96

Cybersecurity Firm Illumio’s Alan Cohen on the Tech Backlash of 2017

Xconomy

One of the largest and most consequential data breaches in 2017 afflicted credit reporting agency Equifax, and it was hardly the only victim. Any year-end review of technology news must also include reports on Russian hacking of the 2016 election campaign, and the manipulation of social media channels to spread false and divisive political messages.

BCMA Day: At ASH ‘18, Cell Therapies For Myeloma Take Center Stage

Xconomy

Take the results of a Phase 3 study just reported today at the American Society of Hematology’s (ASH) yearly meeting in San Diego.

Study 85

Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More

Xconomy

We reported on both those stories and a lot more, including clinical ups and downs and new fundings. Also this week: Reports from. One group of people in dire need of medical relief got good news this week. The first drug for postpartum depression was approved. With its complicated logistics, side effects, and potential high cost, it won’t be for everyone who experiences the condition— 1 of every 9 U.S. women giving birth. But at least it’s an option.

Help 48

VC Confidence Holds Steady in Quarterly Survey, But Reasons Change

Xconomy

Henry Blodget Loves to Blog: The remaking of a disgraced Wall Street analyst

From the Venture Trenches

Henry Blodget , was once the darling of Wall Street covering Internet securities at Merrill Lynch’s and reporting on businesses such as Infospace, Internet Capital Group and Amazon.

15 For ’19: Key Clinical Data to Watch For Next Year (Part 2)

Xconomy

Editor’s note: Alex Lash, Corie Lok, and Frank Vinluan contributed to these reports. On Monday, Xconomy began our annual look ahead at clinical trials that could define biotech and have profound healthcare effects in the coming year.

Study 82

Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More

Xconomy

Intercept (NASDAQ: ICPT ) reported interim data from a Phase 3 study showing its drug, obeticholic acid (OCA), reduced liver scarring in NASH patients. The growing epidemic of the fatty liver disease known as NASH, which has no FDA-approved treatment, has led to a frenzied race among drug companies. This week, one company, Intercept Pharmaceuticals, solidified its lead. But how much will being first to the finish line mean when all is said and done?

News 65

Bio Roundup: Gottlieb Exits, Bristol Defends, Biogen Buys & More

Xconomy

Libertarians who had questioned some of the basic premises of the FDA were in the mix, and even their laissez-faire attitudes had some advocates of a speedier agency worried, as Xconomy reported in early 2017. In early 2017, Scott Gottlieb was considered the most moderate of the potential candidates to head the Food and Drug Administration, which is the most powerful regulator of medical products in the world. It wasn’t a high bar to clear.

Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More

Xconomy

[ Editor’s note: Ben Fidler and Sarah de Crescenzo coauthored this report.] It is here, and then it is gone. But by the time everyone staggers to the airport or back home to sleep in their own beds, the annual few days of the J.P. Morgan Healthcare Conference and everything that mushrooms around it seem just as long as the holiday break—a distant memory!—that —that came just before. In 2020 (yes, that’s really a year), San Francisco might have a new mayor.

U.S. Venture Capital Deals on Pace to Exceed $100B in 2018

Xconomy

30 to more than $84 billion, according to the latest quarterly Venture Monitor report , which is produced by the National Venture Capital Association (NCVA) and PitchBook.

Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More

Xconomy

No executives showed up for the previous hearing, but reports indicate industry has changed its stance under pressure: Both chambers of Congress have kicked up their efforts to battle drug pricing of late, and the Trump administration just announced a plan to overhaul the secretive rebate deals between drug companies and pharmacy benefit managers. If you’re into congressional spectacles, stay tuned later this month.

Diffbot’s A.I. Engine Draws Global Map of Machine Learning Expertise

Xconomy

In February, the Canadian firm Element AI estimated that talent pool at no more than about 90,000, Bloomberg reported.

Bio Roundup: Funding Frenzy, Opioid Summit, Celgene Woes & More

Xconomy

billion, a figure compiled in the Venture Monitor Report. Biotech startups rolled in cash this week. By our count, investors put more than $800 million into life-sciences startups in four days. The money came from a wide range of backers, not just traditional biotech venture firms. It’s early yet in 2018, but the current count could put life-sciences companies on pace to bust past last year’s $17.6 Elsewhere, the U.S.

ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front

Xconomy

[ Ben Fidler co-authored this report.] The European Society for Medical Oncology is wrapping up its annual conference today, replete with clinical data from cancer’s front lines. We’ve sorted the headlines into a few big categories: immunotherapy combinations, breast cancer, lung cancer, the growing class of drugs called PARP inhibitors, and new drugs that treat tumors based on genetic signature.

Study 70